Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcomeAlessandra Iurlo, Pier Mannuccio Mannucci, Alessandro Nobili et al.|Oncotarget|2016Cited by 35
Exploring the role of PARP1 inhibition in enhancing antibody–drug conjugate therapy for acute leukemias: insights from DNA damage response pathway interactionsAndrea Ghelli Luserna di Rorà, Giovanni Martinelli, Andrea Marranci et al.|Journal of Translational Medicine|2024Cited by 5